Home Search Abstracts Browse Oral Sessions Browse Poster Sessions
Session 23  Oral Abstracts
Critical Health Issues in Mothers, Infants, and Children
Tuesday, 10 am-12:15 pm
Room: Room 517a
10:00 am         91 HIV Incidence in Pregnancy and the First Post-partum Year and Implications for PMTCT Programs, Francistown, Botswana, 2008
Lydia Lu*1, K Legwaila2, C Motswere2, M Smit2, W Jimbo2, and T Creek1
1CDC, Atlanta, GA, US and 2CDC, BOTUSA, Botswana
10:15 am         92 Effect of Maternal HAART on Postnatal HIV-1 Transmission after Cessation of Extended Infant Antiretroviral Prophylaxis
T Taha1, J Kumwenda2, S Cole3, D Hoover4, G Kafulafula2, Q Li1, M Thigpen5, M Glenn Fowler6, N Kumwenda1, and Lynne Mofenson*7
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 2Univ of Malawi Coll of Med, Blantyre; 3Univ of North Carolina at Chapel Hill, US; 4Rutgers Univ, Piscataway, NJ, US; 5CDC, Atlanta, GA, US; 6Johns Hopkins Med Insts, Baltimore, MD, US; and 7Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US
10:30 am    93LB Accelerated HIV Disease Progression in African Infants Co-infected with Cytomegalovirus
Andrew Prendergast*1, F Chonco2, K Jeffery1, R Kirton1, C Thobakgale2, G Tudor-Williams3, H Coovadia2, T N'dungu2, B Walker4, and P Goulder1
1Univ of Oxford, UK; 2Univ of KwaZulu-Natal, Durban, South Africa; 3Imperial Coll London, UK; and 4Partners AIDS Res Ctr, Boston, MA, US
10:45 am    94LB Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 (“OCTANE”)
Shahin Lockman and A5208/OCTANE Study Team
Brigham and Women`s Hosp, Boston, MA, US
11:00 am  95aLB A Phase II Study of the Incidence of Nevirapine Resistance Mutations in HIV-infected Thai Women Receiving a Single Intrapartum Dose of NVP followed by a Postpartum Tail of ZDV/ddI or ZDV/ddI/LPV/r: IMPAACT P1032
Russell Van Dyke*1, G Jourdain2, D Shapiro3, N Ngo-Giang-Huong2, L Frenkel4, P Britto3, A Roongpisuthipong5, P Yuthavisuthi6, S Prommas7, T Puthanakit8, and IMPAACT P1032 Protocol Team
1Tulane Univ Hlth Sci Ctr, New Orleans, LA, US; 2Res Inst for Devt, Chiang Mai, Thailand; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Univ of Washington, Seattle, US; 5Sriraj Hosp, Mahidol Univ, Bangkok, Thailand; 6Prapokklao Hosp, Chantaburi, Thailand; 7Bhumibol Adulyadej Hosp, Bangkok, Thailand; and 8Chiang Mai Univ, Thailand
11:15 am  95bLB Efficacy and Safety of 1-Month Post-partum Zidovudine and Didanosine to Prevent HIV-1 Nevirapine Resistance Mutations following Intrapartum Single-dose Nevirapine
M Lallemant1,2, Gonzague Jourdain*1,2, N Ngo-Giang-Huong1,2, S Le Coeur3, T Jarupanich4, T Sukhumanant5, J Achalapong6, N Chotivanich7, J Hemvuttiphan8, S Kanshana9, and Prgm for HIV Prevention and Treatment
1Res Inst for Devt, Chiang Mai, Thailand; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Inst for Population and Social Res, Inst Natl d`Etudes Demographiques, France; 4Regional Hosp, Hat Yai, Thailand; 5Provincial Hosp, Samutsakhon, Thailand; 6Prachanukroh Regional Hosp, Chiang Rai, Thailand; 7Regional Hosp, Chonburi, Thailand; 8Provincial Hosp, Phayao, Thailand; and 9Ministry of Publ Hlth, Thailand
11:30 am         96 Prophylactic Effect of Trimethoprim-Sulfamethoxazole on Malaria in HIV-infected and -exposed Ugandan Children Living in Settings of High Antifolate Resistance
Anne Gasasira*1, D Havlir2, J Achan1, E Charlebois2, T Ruel2, P Rosenthal2, T Sandison3, G Dorsey2, and M Kamya1
1Makerere Univ, Kampala, Uganda; 2Univ of California, San Francisco, US; and 3Univ of Washington, Seattle, US
11:45 am         97 Mortality and Virological Outcomes of 2105 HIV-infected Children Receiving ART in Soweto, South Africa
H Moultrie1, M Yotebieng2, L Kuhn3, and Tammy Meyers*1
1Harriet Shezi Children`s Clinic, Chris Hani Baragwanath Hosp, Univ of the Witwatersrand, Johannesburg, South Africa; 2Univ of North Carolina at Chapel Hill, US; and 3Columbia Univ, New York, NY, US
12:00 pm         98 Double-dose Lopinavir/Ritonavir Provides Insufficient Lopinavir Exposure in Children Receiving Rifampicin-based Anti-TB Treatment
Helen McIlleron*1, Y Ren1, J Nuttall1, A Riddick2, L Kleynhans2, H Rabie3, M Cotton3, B Eley1, C Merry1,4, and G Maartens1
1Univ of Cape Town, South Africa; 2Univ of the Witswatersrand, Johannesburg, South Africa; 3Univ of Stellenbosch, South Africa; and 4Trinity Coll, Dublin, Ireland